Literature DB >> 18057091

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Kirsten Vollmer1, Jens J Holst, Birgit Baller, Mark Ellrichmann, Michael A Nauck, Wolfgang E Schmidt, Juris J Meier.   

Abstract

OBJECTIVE: Defects in glucagon-like peptide 1 (GLP-1) secretion have been reported in some patients with type 2 diabetes after meal ingestion. We addressed the following questions: 1) Is the quantitative impairment in GLP-1 levels different after mixed meal or isolated glucose ingestion? 2) Which endogenous factors are associated with the concentrations of GLP-1? In particular, do elevated fasting glucose or glucagon levels diminish GLP-1 responses? RESEARCH DESIGN AND METHODS: Seventeen patients with mild type 2 diabetes, 17 subjects with impaired glucose tolerance, and 14 matched control subjects participated in an oral glucose tolerance test (75 g) and a mixed meal challenge (820 kcal), both carried out over 240 min on separate occasions. Plasma levels of glucose, insulin, C-peptide, glucagon, triglycerides, free fatty acids (FFAs), gastric inhibitory polypeptide (GIP), and GLP-1 were determined.
RESULTS: GIP and GLP-1 levels increased significantly in both experiments (P < 0.0001). In patients with type 2 diabetes, the initial GIP response was exaggerated compared with control subjects after mixed meal (P < 0.001) but not after oral glucose ingestion (P = 0.98). GLP-1 levels were similar in all three groups in both experiments. GIP responses were 186 +/- 17% higher after mixed meal ingestion than after the oral glucose load (P < 0.0001), whereas GLP-1 levels were similar in both experiments. There was a strong negative association between fasting glucagon and integrated FFA levels and subsequent GLP-1 concentrations. In contrast, fasting FFA and integrated glucagon levels after glucose or meal ingestion and female sex were positively related to GLP-1 concentrations. Incretin levels were unrelated to measures of glucose control or insulin secretion.
CONCLUSIONS: Deteriorations in glucose homeostasis can develop in the absence of any impairment in GIP or GLP-1 levels. This suggests that the defects in GLP-1 concentrations previously described in patients with long-standing type 2 diabetes are likely secondary to other hormonal and metabolic alterations, such as hyperglucagonemia. GIP and GLP-1 concentrations appear to be regulated by different factors and are independent of each other.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057091     DOI: 10.2337/db07-1124

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  123 in total

Review 1.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 2.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 3.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

4.  Entero-insular axis and postprandial insulin differences in African American and European American children.

Authors:  Paul B Higgins; José R Férnández; W Timothy Garvey; Wesley M Granger; Barbara A Gower
Journal:  Am J Clin Nutr       Date:  2008-11       Impact factor: 7.045

Review 5.  Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?

Authors:  Mousumi Bose; Blanca Oliván; Julio Teixeira; F Xavier Pi-Sunyer; Blandine Laferrère
Journal:  Obes Surg       Date:  2008-09-27       Impact factor: 4.129

6.  Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.

Authors:  Marzieh Salehi; Benedict Aulinger; Ronald L Prigeon; David A D'Alessio
Journal:  Diabetes       Date:  2010-03-09       Impact factor: 9.461

7.  Role and development of GLP-1 receptor agonists in the management of diabetes.

Authors:  Chee W Chia; Josephine M Egan
Journal:  Diabetes Metab Syndr Obes       Date:  2009-05-15       Impact factor: 3.168

8.  Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two?

Authors:  Hala Tfayli; Fida Bacha; Neslihan Gungor; Silva Arslanian
Journal:  Diabetes Care       Date:  2009-12-22       Impact factor: 17.152

Review 9.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

10.  Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population.

Authors:  Hung-Ju Lin; Bai-Chin Lee; Yi-Lwun Ho; Yen-Hung Lin; Ching-Yi Chen; Hsiu-Ching Hsu; Mao-Shin Lin; Kuo-Liong Chien; Ming-Fong Chen
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.